Riskpilot← Back to searchSign inGet full accessMedMousa Consulting AB
ABActiveOrg 5566347877Lummelunda Tjaulsvägen 27General medical practice activities · NACE 8621Est. 20020 employees
Revenue 2024
SEK 297K
-34% vs 2023
EBITDA margin
-12.3%
-127% vs 2023
Equity ratio
90.6%
Financial strength
Net profit 2024
SEK 49K
-55% vs 2023
| Revenue | SEK 297K | -34% |
| EBITDA | SEK -36K | -127% |
| Net profit | SEK 49K | -55% |
| Total assets | SEK 1,1M | +0% |
| Equity | SEK 965K | +5% |
| Employees | 0 | — |
Legal name
MedMousa Consulting AB
Org number
5566347877
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
5 november 2002
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva läkarkonsultverksamhet samt konsultverksamhet inom marknadsföring och ekonomi, förvaltning av fastigheter, värdepapper samt övrig fast och lös egendom ävensom idka därmed förenlig verksamhet.
Address
Lummelunda Tjaulsvägen 27
Phone
+46498243773
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 293 | 713 | 509 | 453 | 297 |
| Staff expenses | — | — | −14 | −14 | −20 |
| EBITDA | 174 | 555 | 290 | 137 | −36 |
| Depreciation & amort. | −6 | −0 | — | — | — |
| EBIT | 168 | 555 | 290 | 137 | −36 |
| Net financials | 4 | −4 | −3 | 2 | 72 |
| Profit before tax | 173 | 553 | 287 | 139 | 49 |
| Tax | −38 | −115 | −59 | −29 | — |
| Net profit | 135 | 438 | 228 | 110 | 49 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 564 | 1 139 | 1 026 | 1 068 | 1 064 |
| Equity | 390 | 828 | 806 | 915 | 965 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 160 | 297 | 207 | 138 | 100 |
| Total debt | 160 | 297 | 207 | 138 | 100 |
EBITDA margin
-12.3%
This company
15.8%
Market median
-178% vs market
20202024
Equity ratio
90.6%
This company
38.2%
Market median
+137% vs market
20202024
Return on equity
5.1%
This company
18.4%
Market median
-72% vs market
20202024
Net profit margin
16.6%
This company
8.1%
Market median
+105% vs market
20202024
Asset turnover
0.28×
This company
1.12×
Market median
-75% vs market
20202024
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LE Chief Executive Officer | Chief Executive Officer | 2022 |
AB Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MedMousa Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Evert Svensson | Chief Executive Officer | 0 companies |
| Anne Barbro Mousa Ståhl | Chief Executive Officer | 0 companies |
| Martin Fakhry Metry Mousa | Board of Directors | 0 companies |